Stuart A. Montgomery

The use of cholecystokinin in schizophrenia: a review

S. Montgomery, M. Green, Stuart A. Montgomery, 1988, Psychological Medicine.

Are higher doses more effective in OCD?

N. Fineberg, S. Montgomery, A. Roberts, 1994, European Neuropsychopharmacology.

New developments in the treatment of depression.

S. Montgomery, Stuart A. Montgomery, 1999, The Journal of clinical psychiatry.

The advantages of paroxetine in different subgroups of depression.

S. Montgomery, Stuart A. Montgomery, 1992, International clinical psychopharmacology.

A meta-analysis of the efficacy and tolerability of paroxetine versus tricyclic antidepressants in the treatment of major depression

S. Montgomery, Stuart A. Montgomery, 2001, International clinical psychopharmacology.

The Benefits and Risks of 5-HT Uptake Inhibitors in Depression: Chairman's Introduction

S. Montgomery, Stuart A. Montgomery, 1988, British Journal of Psychiatry.

Brain 5-HT function in obsessive-compulsive disorder

P. Cowen, N. Fineberg, S. Montgomery, 1997, British Journal of Psychiatry.

Inadequate treatment response to des‐enkephalin‐gamma‐endorphin compared with thioridazine and placebo in schizophrenia

S. Hirsch, R. Rimón, S. Montgomery, 1992, Acta psychiatrica Scandinavica.